China channel feed – Endpoints News

China channel feed

A Chinese company is already mass producing Gilead's experimental coronavirus drug

6 years ago

China researchers tout in vitro data for Gilead's antiviral against Wuhan virus — which they are trying to patent

6 years ago

Pandemic fears force Chinese biotech to postpone Hong Kong IPO meetings — Bloomberg

6 years ago

Vas Narasimhan wants Novartis to have a big focus on China. Here’s what that looks like

6 years ago

How do American scientists get embroiled in China scandals? Moffitt investigation sheds some light

6 years ago

Top Harvard chemist caught up in FBI’s 'Thousand Talents' dragnet, accused of lying about Chinese connections, pay

6 years ago

AbbVie donates $1M+ of the HIV drug that China is now recommending for coronavirus treatment

6 years ago

Amgen augments Asia foothold by taking over Astellas joint venture in Japan

6 years ago

Roche cracks China's ADC market open as Kadcyla scores its first breast cancer OK in the country

6 years ago

China’s fourth richest man takes a back seat at the top drugmaker he built

6 years ago

Biopharma's China plan gets a boost from patent protections sealed in now official trade deal

6 years ago

WuXi-backed Adagene scores $69M round led by General Atlantic to push antibodies where Bristol-Myers struggled

6 years ago

BeiGene scores first China OK with PD-1 — to be manufactured by Boehringer Ingelheim

6 years ago

China greenlights homegrown pneumococcal, HPV vaccines for the market — breaking grips by Pfizer, Merck

6 years ago

Chinese court sentences Jiankui He to 3 years in jail — and confirms birth of 3rd CRISPR baby

6 years ago

Banking on Shanghai's biotech boom, this Eli Lilly-backed player grabs $100M to push next-gen I/O therapies

6 years ago

NIH-directed purge of researchers with China ties sweeps up Moffitt CEO Alan List, colleagues

6 years ago

BeiGene's BTK inhibitor fails to beat market leader Imbruvica in key head-to-head study

6 years ago

AstraZeneca joins Merck, Bristol-Myers in China's checkpoint race as regulators OK first PD-L1

6 years ago

Alphamab Oncology rounds out HKEX's second biotech IPO year with $230M raise and high local interest

6 years ago

Shaking up China's PD-(L)1 reimbursement landscape, Innovent, Eli Lilly earn coveted spot on national coverage

6 years ago

Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer

6 years ago

Brii Bio backs infectious disease startup while inking deal for its lead TB drug, doubling down on antibiotics

6 years ago

In a first, FDA green-lights use of a Chinese built cancer therapy — and more are coming

6 years ago

First page Previous page 18 19 202122 23 24 Next page Last page